Frequency of hCD45+ (Percent of Viable Cells) 5. 10. 15. 0. 20. Days post-TIL transfer. D14. No EP KSQ-004EX No EP KSQ-004EX * NSCLC. PDAC. D21. D28. D56. 10. 20. 40 ...

0 10 20 30 40 50 % OT1s of CD8s 0 20 40 60 80 100 % of OT1 ns TH. D. ual inactivationof SOCS1 and Regnase-1 in T Cell Therapies Demonstrated Enhanced

Advancing our pipeline of CRISPR/Cas9-engineered Tumor Infiltrating Lymphocytes (eTIL ®) programs and our partnered first-in-class candidates for the treatment of cancer.

KSQ-001EX is an investigational eTIL therapy manufactured using our ExPRESS™ process in which the SOCS1 gene is inactivated by CRISPR/Cas9 gene editing.; KSQ’s Immune CRISPRomics ® platform identified SOCS1 as a top target, constraining TIL anti-tumor function, engraftment, and persistence.; The U.S. Food and Drug Administration (FDA) has cleared an Investigational New Drug (IND ...

At KSQ, we truly have the ambition to cure. Initially focused on cancer, we believe our approach to finding new targets and therapeutics is unique and has the potential to create potentially transformative medicines with the potential to address many of the shortcomings and challenges associated with current treatments.

%PDF-1.6 %âãÏÓ 341 0 obj > endobj 406 0 obj >/Filter/FlateDecode/ID[82A6A11C79F55042AFB3F3244B0D1E8F>500F9A22E66B3F4A9164FAC867C527A8>]/Index[341 123]/Info 340 0 ...

2024年10月8日 · Anna Truppel-Hartmann is a seasoned medical professional with over 15 years of experience in the pharmaceutical and biotechnology sectors. She earned her medical degree in Switzerland and brings a wealth of expertise and accomplished track record in clinical development, medical affairs, patient engagement, and talent development. She has held key leadership roles at both large

2024年6月14日 · KSQ-4279 is a first-in-class, potent, and selective small-molecule inhibitor of USP1, a protein that regulates DNA damage response (DDR). In July 2023, we entered into a worldwide license and collaboration agreement with Roche for the development and commercialization of KSQ-4279; under the collaboration, Roche has assumed all development responsibilities for KSQ-4279 (as RO7623066).

2021年1月13日 · Collaboration includes two T-cell programs and an expansive discovery program to identify natural killer (NK) cell targets Potential for more than $100M in upfront and preclinical milestone payments, and eligible to receive additional development and commercialization milestone payments for each product KSQ retains a U.S. cost/profit-sharing option on one product, and is entitled to potential

Despite recent advances, there remain significant needs in the treatment of solid tumors, which make up 90% of all cancers. While recent treatment innovations, including immunotherapies, have improved patient care, the CDC reports that more than 600,000 people die of cancer in the U.S. every year. The constant evolution and highly personalized …